EUVIMEDEUVIMED entdecken
Crossref

Survival outcomes and molecular predictors in small cell lung cancer with brain metastases receiving immunotherapy

Lin-Qiang Jiang, Chen-Yang Wan, Jin Kang, Rui Fu, Zi-Hao Chen, Xue-Ning Yang, Hai-Yan Tu, Kai Yin, Yu Zhang, Wen-Zhao Zhong

Journal of Neuro-Oncology · 2026-06 · 178 (2)

DOI: 10.1007/s11060-026-05557-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 08.06.2026. Verfasst von Lin-Qiang Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, China. Hauptthemen laut MEDLINE: Brain Neoplasms, Small Cell Lung Carcinoma, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 37 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Youth Fund of the National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the real-world efficacy of chemoimmunotherapy combined with brain radiotherapy and to explore prognostic biomarkers in patients with small cell lung cancer (SCLC) and brain metastases (BM). METHODS: We retrospectively analyzed 133 consecutive patients with de novo SCLC-BM. Patients were categorized into a chemotherapy-only cohort (n = 54) and a chemoimmunotherapy cohort (n = 79). Survival outcomes were assessed. Exploratory analyses included serum markers (NSE, CEA) and tissue molecular subtypes (SCLC-A/N/P/TN) identified via multiplex immunofluorescence. RESULTS: Chemoimmunotherapy was significantly associated with prolonged median progression-free survival (6.1 vs. 5.1 months, P = 0.034) and overall survival (10.2 vs. 9.0 months, P = 0.019) compared to chemotherapy alone. Time-dependent multivariate analysis confirmed that both chemoimmunotherapy (adjusted HR = 0.65, P = 0.032) and brain radiotherapy (time-dependent HR = 0.63, P = 0.040) were independent protective factors for overall survival. Notably, the longest median overall survival (15.2 months) was observed in patients receiving the combination of chemoimmunotherapy and brain radiotherapy. In exploratory biomarker analyses, high baseline NSE coupled with low CEA levels correlated with poor prognosis (HR = 6.47). Furthermore, distinct molecular heterogeneity was observed; SCLC-N and SCLC-P subtypes were associated with significantly inferior survival compared to SCLC-A and SCLC-TN phenotypes. CONCLUSION: First-line atezolizumab plus chemotherapy is associated with favorable survival outcomes in patients with SCLC brain metastases, and the longest survival was observed when combined with brain radiotherapy. Additionally, exploratory analyses suggest that high neuroendocrine burden and specific molecular subtypes (SCLC-N/P) may serve as potential prognostic biomarkers, warranting prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsSmall Cell Lung CarcinomaLung NeoplasmsImmunotherapyHumansFemaleMaleRetrospective StudiesAgedMiddle AgedPrognosisBiomarkers, TumorSurvival RateFollow-Up Studies

Stichwörter der Autor:innen

Brain metastasisImmunotherapyRadiotherapyReal-world evidenceSmall cell lung cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • School of Medicine, South China University of Technology, Guangzhou, China.
  • Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,…
  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. dsyinkai@126.com.
  • School of Medicine, South China University of Technology, Guangzhou, China. luck_2001@126.com.
  • School of Medicine, South China University of Technology, Guangzhou, China. syzhongwenzhao@scut.edu.cn.

Förderung

  • China Postdoctoral Science Foundation
  • Youth Fund of the National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • The Guangdong Provincial Key Area R&D Program
  • National Key Research and Development Program for the Prevention and Treatment of Cancer, Cardiovascular and Cerebrovascular Diseases, Respiratory and Metaboli…
  • National Natural Science Foundation of China
  • Major Joint Special Project of the National Natural Science Foundation of China on Key Scientific Issues in Lung Cancer
  • National High-Level Talent Special Support Program

Zitieren

APA

Jiang, L. Q., Wan, C. Y., Kang, J., Fu, R., Chen, Z. H., Yang, X. N., Tu, H. Y., Yin, K., Zhang, Y., & Zhong, W. Z. (2026). Survival outcomes and molecular predictors in small cell lung cancer with brain metastases receiving immunotherapy. Journal of Neuro-Oncology, 178(2). https://doi.org/10.1007/s11060-026-05557-9

Vancouver

Jiang LQ, Wan CY, Kang J, Fu R, Chen ZH, Yang XN, et al. Survival outcomes and molecular predictors in small cell lung cancer with brain metastases receiving immunotherapy. Journal of Neuro-Oncology. 2026;178(2). doi:10.1007/s11060-026-05557-9

BibTeX
@article{Jiang2026,
  author = {Jiang, Lin-Qiang and Wan, Chen-Yang and Kang, Jin and Fu, Rui and Chen, Zi-Hao and Yang, Xue-Ning and Tu, Hai-Yan and Yin, Kai and Zhang, Yu and Zhong, Wen-Zhao},
  title = {Survival outcomes and molecular predictors in small cell lung cancer with brain metastases receiving immunotherapy},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  volume = {178},
  number = {2},
  doi = {10.1007/s11060-026-05557-9}
}
Kostenlos starten →